FDA WARNING_LETTER - AkivaMed Inc. - July 08, 2020
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
On July 23, 2020, the FDA issued a Warning Letter to AkivaMed, following a July 8, 2020 review of their website, www.akivamed.com. The FDA observed that AkivaMed was offering a "COVID-19 Antibody Rapid Test Kit" for sale directly to consumers for at-home use in the United States.
The FDA determined this product is a device under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h), as it is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.
The product is deemed adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because AkivaMed lacks an approved premarket approval (PMA) application or an investigational device exemption (IDE). It is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), as the firm failed to notify the FDA of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S
ID · 52cdf197-0ff8-4977-bf17-32180acc4779
Full citation text and observation details available on the Dashboard.